A Pharmacor Analyst Call from Decision Resources

To ensure that our emails get to your inbox, please add Decision_Resources@mail.vresp.com to your email address book or safe senders list.
PLEASE DO NOT REPLY TO THIS EMAIL; CONTACT YOUR ACCOUNT REPRESENTATIVE DIRECTLY.

If this message does not display properly, please click here to launch your browser.

Prolia is Approved for the Treatment of Postmenopausal Osteoporosis: How Will It Compete in This Mature, Crowded Market?

Based on our Pharmacor advisory service entitled Osteoporosis, Decision Resources is offering an exclusive analyst call entitled Prolia is Approved for the Treatment of Postmenopausal Osteoporosis: How Will It Compete in This Mature, Crowded Market? Because this presentation will feature updates to the Osteoporosis topic, it is ONLY available to purchasers of this Pharmacor advisory service

Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call.

Amgen’s Prolia was recently approved in the United States and Europe for the treatment of postmenopausal osteoporosis. Prolia is the first monoclonal antibody approved for the treatment of osteoporosis. Although the drug carries the potential to improve patient compliance, Prolia will compete with a number of established compounds and generic agents. Can Prolia hope to achieve substantial market share during this period of increased fiscal tightening among national health care systems?

This 15-minute analyst call, presented by Decision Resources Analyst Matthew Scutcher, Ph.D., will answer the following questions:

What are the advantages of Prolia over currently available osteoporosis treatments?
What clinical evidence supports the use of Prolia over current standards of care?
What do key opinion leaders say about this drug and where do they predict the drug will be used in the current treatment paradigm?
What is Decision Resources’ sales forecast through 2019 for Prolia and the overall osteoporosis market?

Dr. Scutcher will conduct a live Q & A session following the presentation.

Registration

Prolia is Approved for the Treatment of Postmenopausal Osteoporosis: How Will It Compete in This Mature, Crowded Market?

June 17, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below.

In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com

In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be

In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp

Date & Time
Thursday, June 17, 2010
10 a.m. U.S. Eastern Time,
4 p.m. Central European Time

Duration
15 minutes

Matthew Scutcher, Ph.D. is an analyst on the cardiovascular and metabolic disorders team at Decision Resources. Prior to joining the company Dr. Scutcher was a postdoctoral fellow in the Department of Bioengineering at Imperial College London, where he conducted research on the pulsatile shear stress responses of aortic endothelial cells. He earned his M.Eng in Chemical Engineering and Chemical Technology at Imperial College London and completed his Ph.D. in Biochemical Engineering at University College London, where he developed control systems for a vascular tissue engineering bioreactor designed to engineer coronary artery bypass grafts from bone marrow-derived stem cells.

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 260 Charles Street • Waltham, MA 02453

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2010 Decision Resources, Inc. All rights reserved.